Cargando…
48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)
Autores principales: | Arastéh, K, Ward, A, Plettenberg, A, Livrozet, JM, Cordes, C, Winston, A, Wang, E, Quinson, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The International AIDS Society
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113048/ http://dx.doi.org/10.1186/1758-2652-13-S4-P45 |
Ejemplares similares
-
Comparison between 200 mg QD and 100 mg BID oral celecoxib in the treatment of knee or hip osteoarthritis
por: Zeng, Chao, et al.
Publicado: (2015) -
Twelfth-Position
Deuteration of Nevirapine
Reduces 12-Hydroxy-Nevirapine
Formation and Nevirapine-Induced Hepatocyte Death
por: Heck, Carley J. S., et al.
Publicado: (2020) -
Incidence and Determinants of Nevirapine and Efavirenz-Related Skin Rashes in West Africans: Nevirapine's Epitaph?
por: Sarfo, Fred Stephen, et al.
Publicado: (2014) -
Preparation and Characterisation of Nevirapine Oral Nanosuspensions
por: Raju, Anju, et al.
Publicado: (2014) -
Solid-State Characterization of Nevirapine
por: Sarkar, Mahua, et al.
Publicado: (2008)